For the Inventor, By the Inventor

Enter assignee name

Bridgewater, NJ, United States of America

Aventis Pharmaceuticals Products Inc.

Calculating rank

USPTO Granted Patents = 23

Trademarks = 2

Forward Citations = 675

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Alfred P Spada (6 out of 52 patents)

Benoit J Vanasse (6 out of 9 patents)

Scott I Klein (5 out of 21 patents)

4. Kevin Richard Guertin (4 out of 16 patents)

5. Adam W Sledeski (3 out of 9 patents)

6. Michael R Myers (3 out of 37 patents)

7. James P Sherbine (3 out of 7 patents)

8. Richard F Labaudiniere (3 out of 12 patents)

9. Patrick Leon (3 out of 24 patents)

10. Joseph M Salvino (2 out of 46 patents)

11. Wei He (2 out of 46 patents)

12. George C Morton (2 out of 22 patents)

13. Patrice Denefle (2 out of 18 patents)

14. Martin P Maguire (2 out of 24 patents)

15. Rick G Woodward (2 out of 4 patents)

23 patents: Sort by Forward Citations

1. 7041497 - Nuclear factor κB inducing factor (2006-05-09),

2. 6391980 - Activated and conjugated polystyrene substrate (2002-05-21),

3. 6361936 - Activated and conjugated polystyrene substrate (2002-03-26),

4. 6323227 - Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides (2001-11-27),

5. 6307054 - Process for preparing 2,4- dihydroxypyridine and 2,4- dihydroxy-3-nitropyridine (2001-10-23),

6. 6306873 - Substituted &bgr;-thiocarboxylic acids (2001-10-23),

7. 6277865 - Piperididinyl and N-amidinopiperidinyl derivatives (2001-08-21),

8. 6274705 - Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides (2001-08-14),

9. 6258596 - Variants of apolipoprotein A-I (2001-07-10),

10. 6248841 - Elastomer treatment process to decrease peroxide levels (2001-06-19),

11. 6245760 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2001-06-12),

12. 6235909 - Preparation of is-[1A,2B,3B,4A(S*)]-4-[7-[[1-(3-chloro-2-Thienyl)methyl]amino]-3H-imidazo [4,5-B]pyridin-3-YL]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide (2001-05-22),

13. 6184382 - Process for preparing N6-substituted adenosine derivatives (2001-02-06),

14. 6180759 - Process for the preparation of azacycloalkylakanoyl pseudotetrapeptides (2001-01-30),

15. 6180632 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2001-01-30),

Company Overview

Aventis Pharmaceuticals Products Inc., based in Bridgewater, NJ, specializes in the development and manufacturing of innovative pharmaceutical products. The company focuses on a range of therapeutic areas, including oncology, cardiovascular health, and infectious diseases. With a commitment to advancing healthcare solutions, Aventis leverages cutting-edge research and technology to enhance patient outcomes. Its strategic initiatives aim to address unmet medical needs and improve the quality of life for patients globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

23 Patents

#15 in Bridgewater, NJ

#559 in New Jersey

#14,450 in US

#27,736 in the World

Bridgewater, NJ, United States of America

Aventis Pharmaceuticals Products Inc.

Forward Citations = 675

70 inventors:

Alfred P Spada (6 out of 52 patents)

Benoit J Vanasse (6 out of 9 patents)

Scott I Klein (5 out of 21 patents)

4. Kevin Richard Guertin (4 out of 16 patents)

5. Adam W Sledeski (3 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aventis Pharmaceuticals Products Inc.. Retrieved from https://idiyas.com/company/aventis-pharmaceuticals-products

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…